141 related articles for article (PubMed ID: 16979895)
1. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents.
Yoshida K; Nakayama K; Yokomizo Y; Ohtsuka M; Takemura M; Hoshino K; Kanda H; Namba K; Nitanai H; Zhang JZ; Lee VJ; Watkins WJ
Bioorg Med Chem; 2006 Dec; 14(24):8506-18. PubMed ID: 16979895
[TBL] [Abstract][Full Text] [Related]
2. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 5: Carbon-substituted analogues at the C-2 position.
Yoshida K; Nakayama K; Kuru N; Kobayashi S; Ohtsuka M; Takemura M; Hoshino K; Kanda H; Zhang JZ; Lee VJ; Watkins WJ
Bioorg Med Chem; 2006 Mar; 14(6):1993-2004. PubMed ID: 16290941
[TBL] [Abstract][Full Text] [Related]
3. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
Yoshida K; Nakayama K; Ohtsuka M; Kuru N; Yokomizo Y; Sakamoto A; Takemura M; Hoshino K; Kanda H; Nitanai H; Namba K; Yoshida K; Imamura Y; Zhang JZ; Lee VJ; Watkins WJ
Bioorg Med Chem; 2007 Nov; 15(22):7087-97. PubMed ID: 17869116
[TBL] [Abstract][Full Text] [Related]
4. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 4: Addressing the problem of poor stability due to photoisomerization of an acrylic acid moiety.
Nakayama K; Kuru N; Ohtsuka M; Yokomizo Y; Sakamoto A; Kawato H; Yoshida K; Ohta T; Hoshino K; Akimoto K; Itoh J; Ishida H; Cho A; Palme MH; Zhang JZ; Lee VJ; Watkins WJ
Bioorg Med Chem Lett; 2004 May; 14(10):2493-7. PubMed ID: 15109639
[TBL] [Abstract][Full Text] [Related]
5. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
[TBL] [Abstract][Full Text] [Related]
6. Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa.
Hirakata Y; Kondo A; Hoshino K; Yano H; Arai K; Hirotani A; Kunishima H; Yamamoto N; Hatta M; Kitagawa M; Kohno S; Kaku M
Int J Antimicrob Agents; 2009 Oct; 34(4):343-6. PubMed ID: 19615866
[TBL] [Abstract][Full Text] [Related]
7. In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection.
Boutoille D; Jacqueline C; Le Mabecque V; Potel G; Caillon J
Int J Antimicrob Agents; 2009 May; 33(5):417-20. PubMed ID: 19157801
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
Hocquet D; Nordmann P; El Garch F; Cabanne L; Plésiat P
Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
[TBL] [Abstract][Full Text] [Related]
9. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.
Nakayama K; Ishida Y; Ohtsuka M; Kawato H; Yoshida K; Yokomizo Y; Ohta T; Hoshino K; Otani T; Kurosaka Y; Yoshida K; Ishida H; Lee VJ; Renau TE; Watkins WJ
Bioorg Med Chem Lett; 2003 Dec; 13(23):4205-8. PubMed ID: 14623002
[TBL] [Abstract][Full Text] [Related]
10. [Drug screening model acting on out-membrane protein OprM in pseudomonas aeruginosa efflux pump system].
Tian R; Yu LY; Xiao CL; Zuo L; Yao TJ; Yang LX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):359-63. PubMed ID: 15379256
[TBL] [Abstract][Full Text] [Related]
11. MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin.
Hocquet D; Roussel-Delvallez M; Cavallo JD; Plésiat P
Antimicrob Agents Chemother; 2007 Apr; 51(4):1582-3. PubMed ID: 17220417
[No Abstract] [Full Text] [Related]
12. The mode of action of 2-(thiazol-2-ylthio)-1beta-methylcarbapenems against Pseudomonas aeruginosa: the impact of outer membrane permeability and the contribution of MexAB-OprM efflux system.
Eguchi K; Ueda Y; Kanazawa K; Sunagawa M; Gotoh N
J Antibiot (Tokyo); 2007 Feb; 60(2):129-35. PubMed ID: 17420563
[TBL] [Abstract][Full Text] [Related]
13. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 3: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore model.
Nakayama K; Kawato H; Watanabe J; Ohtsuka M; Yoshida K; Yokomizo Y; Sakamoto A; Kuru N; Ohta T; Hoshino K; Yoshida K; Ishida H; Cho A; Palme MH; Zhang JZ; Lee VJ; Watkins WJ
Bioorg Med Chem Lett; 2004 Jan; 14(2):475-9. PubMed ID: 14698185
[TBL] [Abstract][Full Text] [Related]
14. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
Wolter DJ; Black JA; Lister PD; Hanson ND
J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
[TBL] [Abstract][Full Text] [Related]
15. Gene-specific silencing induced by parallel complementary RNA in Pseudomonas aeruginosa.
Liu YS; Zhang YQ; Yang LX; Yao TJ; Xiao CL
Biotechnol Lett; 2009 Oct; 31(10):1571-5. PubMed ID: 19543856
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship of 2-hydroxy-2-aryl-2,3-dihydro-imidazo[1,2-a]pyrimidinium salts and 2N-substituted 4(5)-aryl-2-amino-1H-imidazoles as inhibitors of biofilm formation by Salmonella Typhimurium and Pseudomonas aeruginosa.
Steenackers HP; Ermolat'ev DS; Savaliya B; Weerdt AD; Coster DD; Shah A; Van der Eycken EV; De Vos DE; Vanderleyden J; De Keersmaecker SC
Bioorg Med Chem; 2011 Jun; 19(11):3462-73. PubMed ID: 21550812
[TBL] [Abstract][Full Text] [Related]
17. Functional interaction sites of OprM with MexAB in the Pseudomonas aeruginosa multidrug efflux pump.
Yoshihara E; Eda S; Kaitou S
FEMS Microbiol Lett; 2009 Oct; 299(2):200-4. PubMed ID: 19709308
[TBL] [Abstract][Full Text] [Related]
18. Contributions of IMP-10 metallo-beta-lactamase, the outer membrane barrier and the MexAB-OprM efflux system to high-level carbapenem resistance in Pseudomonas aeruginosa.
Zhao WH; Hu Z; Chen G; Ito R; Hu ZQ
Chemotherapy; 2009; 55(3):168-74. PubMed ID: 19420932
[TBL] [Abstract][Full Text] [Related]
19. A peptide based on homologous sequences of the β-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa.
Mori N; Ishii Y; Tateda K; Kimura S; Kouyama Y; Inoko H; Mitsunaga S; Yamaguchi K; Yoshihara E
J Antimicrob Chemother; 2012 Sep; 67(9):2173-81. PubMed ID: 22628248
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of 3-(1,3,4-thiadiazol-2-yl)pyrazolo[1,5-a] pyrimidine derivatives as potential antimicrobial agents.
Auzzi G; Costanzo A; Bruni F; Clauser M; Guerrini G; Selleri S; Pecori Vettori L
Farmaco; 1990 Nov; 45(11):1193-205. PubMed ID: 2128451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
